Example: Heart Attack

Search clinical trials for: Cytarabine

Total 1560 results

NCT05886049

Not yet recruiting

Testing the Addition of an Anti-cancer Drug, SNDX-5613, to the Standard Chemotherapy Treatment (Daunorubicin and Cytarabine) for Newly Diagnosed Patients With Acute Myeloid Leukemia That Has Changes in NPM1 or MLL/KMT2A Gene

Acute Myeloid Leukemia With KMT2A Rearrangement Acute Myeloid Leukemia With NPM1 Mutation
NCT05876832

Not yet recruiting

A Study of XY0206 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory AML With FLT3-ITD-Mutation (ALIVE)

Acute Myeloid Leukemia With FLT3/ITD Mutation
NCT05870995

Recruiting

Chemotherapy CLAGE-Ven Sequential With Reduced Dose of MBF for Refractory Acute Myelodi Leukemia

Refractory Leukemia
NCT05863832

Recruiting

Study to Assess the Safety & Efficacy of Oral Ciprodiazole Versus Currently Used Ciprofloxacin & Metronidazole (CIPRO-001)

Surgical Site Infections
NCT05863845

Not yet recruiting

Efficacy and Safety of Venetoclax Combined With BEAM Pretreatment in Autologous Transplantation for DLBCL

Diffuse Large B Cell Lymphoma
NCT05849662

Not yet recruiting

A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia

Neurofibromatosis 1 JMML Leukemia, Juvenile Myelomonocytic JCML CBL Syndrome
NCT05844735

Recruiting

A Randomized Placebo- and Active Comparator-controlled Study to Evaluate the Photosafety of SAR441566

Rheumatoid Arthritis
NCT05829434

Not yet recruiting

Magrolimab Plus Intensive Chemotherapy in Newly Diagnosed AML or HR-MDS (MAGROLIC)

Acute Myeloid Leukemia Myelodysplastic Neoplasm
NCT05827549

Not yet recruiting

Evaluation of Treatment Efficacy According to Risk Group in Relapsed Childhood Acute Lymphoblastic Leukemia (ReCALL)

Acute Lymphoid Leukemia
NCT05814718

Not yet recruiting

Modified BEAM Regimen for T Cell Lymphoma Underwent ASCT

Conditioning Autologous Stem Cell Transplantation
NCT05814731

Not yet recruiting

Study on the Efficacy and Safety of MA-BUCY2 Conditioning in High-risk AML Patients Underwent Haplo-HSCT

Conditioning Haploidentical Stem Cell Transplantation
NCT05813132

Recruiting

BeEAM Versus CEM in Lymphoma Patients as a Conditioning Regimen Before Autologous Hematopoietic Cell Transplantation

Lymphoma
NCT05807932

Not yet recruiting

Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAML

Myelodysplastic Syndromes Chronic Myelomonocytic Leukemia Secondary Acute Myeloid Leukemia
NCT05807347

Recruiting

Venetoclax Combined With Azacitidine and CAG in Refractory/Relapse Acute Myeloid Leukemia

Refractory/Relapse Acute Myeloid Leukemia
NCT05807659

Recruiting

Fractionated Busulfan Conditioning Regimen for Allo-HSCT in Non-remission Myeloid Malignancies

Myeloid Malignancies
NCT05805098

Recruiting

Venetoclax Combined With Homoharringtonine and Cytarabine in Induction for AML (VHA)

Acute Myeloid Leukemia
NCT05805072

Not yet recruiting

Selinexor and HAAG With/Without HMA in Relapsed/Refractory Acute Leukemia (AML) Patients

Relapsed/Refractory AML
NCT05801835

Not yet recruiting

A Bioequivalence Study of (Cytarabine: Daunorubicin) Liposome for Injection

Acute Myeloid Leukemia
NCT05780879

Not yet recruiting

A Proof of Concept Pilot Study of the Addition of Venetoclax to Standard Remission Induction Chemotherapy Fludarabine, Cytarabine, and Granulocyte Colony Stimulating Factor (G-CSF) (FLAG) for Frontline Therapy of Secondary Acute Myeloid Leukemia

Secondary Acute Myeloid Leukemia
NCT05766514

Not yet recruiting

Phase II Prospective Randomized Control Trial of Cladribine and Low-Dose Cytarabine (LoDAC) Alternating With Decitabine vs. Hypomethylating Agents (HMA) Plus Venetoclax as Frontline Therapy for AML or High-Grade MDS in Patients Unfit for Intensive Induction

Acute Myeloid Leukemia Myelodysplastic Syndromes
NCT05761171

Not yet recruiting

A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia

Recurrent Acute Lymphoblastic Leukemia Refractory Acute Lymphoblastic Leukemia Recurrent Mixed Phenotype Acute Leukemia Refractory Mixed Phenotype Acute Leukemia Refractory Acute Leukemia of Ambiguous Lineage Recurrent Acute Leukemia of Ambiguous Lineage
NCT05751044

Not yet recruiting

HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies (HEM-iSMART B)

Acute Lymphoblastic Leukemia Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory
NCT05749276

Not yet recruiting

Escalation of Doses of Daratumumab in Combination With Chemotherapy (Idarubicin and Cytarabine) in Patients of 60 Years Old or More With Adverse Risk Acute Myeloblastic Leukemia (AML) (DARALAM) (DARALAM)

Adult Patients With Adverse Risk Acute Myeloblastic Leukemia
NCT05745714

Not yet recruiting

HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies (HEM-iSMART C)

Acute Lymphoblastic Leukemia, in Relapse Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory
NCT05740449

Not yet recruiting

HEM-iSMART-A: Decitabine / Venetoclax and Navitoclax in Pediatric Patients With Relapsed or Refractory Hematological Malignancies (HEM-iSMART A)

Acute Lymphoblastic Leukemia, in Relapse Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory
NCT05739630

Recruiting

M-PTCy vs BuCy in Haploidentical HSCT for Acute Leukemia

Acute Leukemia
NCT05735184

Not yet recruiting

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, or 7+3 in Patients With AML

Acute Myeloid Leukemia Acute Myeloid Leukemia, in Relapse Myeloid Sarcoma Acute Myeloid Leukemia Recurrent Mixed Phenotype Acute Leukemia Mixed Lineage Acute Leukemia Refractory AML NPM1 Mutation Mixed Lineage Leukemia Gene Mutation AML With Mutated NPM1
NCT05726110

Recruiting

Selinexor in Combination With HAD or CAG Rregimens in Relapsed or Refractory Acute Myeloid Leukemia

Relapsed or Refractory Acute Myeloid Leukemia
NCT05712278

Not yet recruiting

A Study to Investigate Use of Off-the-shelf Natural Killer (NK) Cells (SAR445419) in Relapsed/Refractory Acute Myeloid Leukemia

Acute Myeloid Leukaemia
NCT05697510

Recruiting

Dose-escalation of Siltuximab in Combination With Idarubicin and Cytarabine Chemotherapy in Patients With Acute Myeloblastic Leukaemia (AML) With Poor Prognosis: SILTUXILAM (SILTUXILAM)

Acute Myeloid Leukemia (AML)
NCT05681260

Recruiting

Capizzi Escalating Methotrexate Versus High Dose Methotrexate in Children With Newly Diagnosed T-cell Lymphoblastic Lymphoma (T-LBL)

T-cell Lymphoblastic Lymphoma
NCT05681403

Not yet recruiting

Clinical Study of Improved BEAM Conditioning Regimen for ASCT in Lymphoma

Lymphoma Autologous Hematopoietic Stem Cell Transplantation
NCT05667402

Not yet recruiting

Clinical Study of TBF Regimen in Allo-HSCT in Patients With CNS Leukemia

Allogeneic Hematopoietic Stem Cell Transplantation Central Nervous System Leukemia
NCT05665114

Recruiting

Natural Killer(NK) Cell Therapy in r/r AML

AML, Adult
NCT05665075

Recruiting

Natural Killer (NK) Cell Therapy Targeting CD33 in Acute Myeloid Leukemia

AML, Adult

Search clinical trials for: Cytarabine

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kyrgyzstan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations